

AIM OF THE COURSE

This symposium aims to cover a broad range of topics in **HRQOL, Symptom Research and Cancer clinical trials**. It will address recent developments of EORTC tools, as well as other measures for use in clinical trials, but also have a broader focus including discussing international developments and research in oncology. The faculty are international key opinion leaders in their field who will be able to provide a diverse view on HRQOL. Participants will learn aspects of designing, conducting and analyses of HRQOL in clinical trials.

HOTEL & REGISTRATION INFORMATION

ACCOMMODATION

Participants requiring hotel accommodation may book directly with the hotels suggested on the EORTC website:

<http://www.eortc.be/about/hotels.htm>

• **Hotel Astrid (Place du Samedi, 11 - 1000 Brussels)**

Phone +32 2 219 31 19 - Fax +32 2 219 31 70 - Email: info@astridhotel.be

• **Hotel Atlas (Rue du Vieux Marché aux Grains, 30 - 1000 Brussels)**

Phone +32 2 502 60 06 - Fax +32 2 502 69 35 - Email: sales@atlas.be

REGISTRATION

On-line registration is available at:

www.eortc.be/Seminar/QoL_Probe_2011/ProbeRegistrationForm.aspx

ATTENDANCE TO THIS MEETING IS FREE

As the number of places on this course is limited, participants are encouraged to register as soon as possible.

Advanced registration will be required.

The deadline for registration is 1st July 2011.

Fellowship Offers

30 fellowships of up to 400 Euros will be awarded to young academics (under 35 years old), advanced clinical students or those from developing countries. This will help to cover a part of the costs (e.g. travel, hotel, taxi fares, etc) to attend the symposium. To apply, send your CV and a motivation letter to rossella.guzzo@eortc.be

CME Accreditation

We expect the program of this event to be accredited by ESMO with 15 ESMO-MORA points Category 1 and by the Accreditation Council of Oncology in Europe (ACOE) with 12 European CME credits.

INVITED FACULTY

Matti AAPRO, Clinique de Genolier, CH
Kristin BJORDAL, Norwegian Radium Hospital, NO
Andrew BOTTOMLEY, EORTC Headquarters, BE
Corneel COENS, EORTC Headquarters, BE
Louis DENIS, Europa Uomo Oncology Center Antwerp, BE
Henning FLECHTNER, Otto-Von-Guericke University Magdeburg, DE
Patricia GARCIA-PRIETO, European Cancer Patient Coalition (ECPC), BE
Jan GEISSLER, CML Advocates Network, DE
Carolyn GOTAY, University of British Columbia, CA
Eva GREIMEL, Medical University, Graz, AT
Colin JOHNSON, Univ. Surg. Unit, Southampton General Hosp, UK
Paul KIND, University of York, UK
Michael KOLLER, University of Regensburg, DE
Dagmara KULIS, EORTC Headquarters, BE
John MARINGWA, Quantitative Solutions, NL
Francesca MARTINELLI, EORTC Headquarters, BE
Marisa MATIAS, Member of European Parliament, BE
David McNAMEE, The Lancet, UK
Françoise MEUNIER, EORTC Headquarters, BE
Carol MOINPOUR, Fred Hutchinson Cancer Research Center, US
Joana NAMORADO, European Commission, BE
Sarunas NARBUTAS, European Cancer Patient Coalition (ECPC), BE
David OSOBA, Quality of Life Consulting, CA
Mira PAVLOVIC, Deputy Director DEMESP (HAS), FR
Heide PREUSS, Mamazone Women, DE
Chantal QUINTEN, EORTC Headquarters, BE
Bryce REEVE, University of Carolina at Chapel Hill, US
Jolie RINGASH, The Princess Margaret Hospital, CA
Jeff SLOAN, Mayo Clinic, US
Martin TAPHOORN, Medisch Centrum Haaglanden-westende, NL
Yasuhiro TORIGOE, Genentech, US
Galina VELIKOVA, St. James's University Hospital, UK
Ulrich WEDDING, University of Jena, DE
Joachim WEIS, Clinic of Tumorbiology University of Freiburg, DE

For further information, please contact:

Ms. Rossella GUZZO, EORTC Quality of Life Department
Avenue E. Mounier, 83, Bte 11 • 1200 Brussels, Belgium
Phone: +32 2 774 10 57 • Fax: +32 2 779 45 68
E-mail: rossella.guzzo@eortc.be

www.eortc.be/probe



2nd EORTC Symposium

Quality of Life, Symptom Research and Patient Reported Outcomes in Cancer Clinical Trials

FREE REGISTRATION



7 - 9 September 2011

To be held at
the European Parliament

Brussels - Belgium

Chairman

Andrew Bottomley, PhD
EORTC Assistant Director
Head of EORTC Quality of Life Department



Wednesday 7th September 2011

Quality of Life Workshops

- 13.00 - 13.30 Registration & welcome coffee**
13.30 - 15.00 Translation of PROs: methodological aspects and implications for international clinical trials (M. Koller, D. Kulis, E. Greimel)
Clinical Significance (J. Maringwa, D. Osoba)
- 15.00 - 15.30 Coffee break**
15.30 - 17.00 Patient Experience (H. Preuss, S. Narbutas, P. Garcia-Prieto)
Enhancing HRQOL measurement through use of Item Response Theory [IRT] (B. Reeve, J. Sloan)

Thursday 8th September 2011

**Academic and methodological issues
Session Chairs: A. Bottomley & H. Flechtner**

- 08.00 - 09.00 Registration & welcome coffee**
09.00 - 09.10 Introduction (F. Meunier)
09.10 - 09.20 Key Note Address (M. Matias)
09.20 - 09.30 Welcome and aims of the Symposium (A. Bottomley)
09.30 - 10.00 Basics of design and analysis of HRQOL protocols (C. Coens)
10.00 - 10.20 How to make a HRQOL Measure the EORTC way: New Developments (E. Greimel)
- 10.20 - 10.40 Coffee break**

**Methodology of trials with HRQOL issues
Session Chairs: C. Quinten & G. Velikova**

- 10.40 - 11.10 HRQOL in daily practice – Experience with EORTC tools (G. Velikova)
11.10 - 11.40 Using HRQOL as a prognostic factor - Fact or fiction (C. Quinten)
11.40 - 12.10 Does it make sense to assess HRQOL in brain cancer (M. Taphoorn)
12.10 - 12.40 Do medical journals understand PRO and QOL (D. McNamee)
- 12.40 - 13.40 Lunch/Coffee break**

Understanding optimal analysis of HRQOL data techniques for cancer clinical trials / Session Chair: C. Moinpour

- 13.40 - 14.05 Complex analysis strategies for longitudinal data (C. Coens)
14.05 - 14.30 Cluster Analysis: Can it Add to your Data ? (F. Martinelli)
14.30 - 15.00 Fatigue: Can we measure it in cancer clinical trials? (J. Weis)
15.00 - 15.30 Multiple Myeloma and Novel Therapies (A. Bottomley)
15.30 - 16.00 Using HRQOL data in economic analyses: Mapping the methodological minefield (P. Kind)

Thursday 8th September 2011 (Cont'd)

Debate - Session Chairs: H. Flechtner & C. Gotay

- 16.00 - 16.30 Genetics and HRQOL - Related or not - Pro (J. Sloan)
16.30 - 17.00 Genetics and HRQOL - Related or not - Con (H. Flechtner)
- 20.00 GALA DINNER**

Friday 9th September 2011

**Patients and Regulatory Views of HRQOL
Session Chair: M. Aapro**

- 08.30 - 08.40 Welcome and plan of the day (M. Aapro)
08.40 - 09.10 Why HRQOL is important to patients (L. Denis)
09.10 - 09.40 Getting Patients Included in Clinical Trials (H. Preuss, S. Narbutas, P. Garcia-Prieto, J. Geissler)
09.40 - 10.10 EMEA experience with HRQOL submissions (M. Pavlovic)
10.10 - 10.40 What do companies do with the FDA PRO guidance? (Y. Torigoe)
10.40 - 11.10 Ethical issues in EU research: Special issue for clinical and translational applications (J. Namorado)
- 11.10 - 11.30 Coffee break**

**International Cooperative Groups and HRQOL (Lessons Learned)
Session Chair: D. Osoba**

- 11.30 - 12.00 NCIC-CTG experience and success in cancer clinical trials (J. Ringash)
12.00 - 12.30 EORTC experience and success in cancer clinical trials (A. Bottomley)
12.30 - 13.00 Biases in assessing patient-reported outcomes (C. Gotay)
- 13.00 - 14.00 Lunch**
- 14.00 - 14.30 The use of HRQOL as endpoint in radiotherapy clinical trials (K. Bjordal)
14.30 - 15.00 Measuring changes in symptom status and QOL: Group vs individual level assessment (C. Moinpour)

**Translations and the Future for HRQOL
Session Chair: J. Sloan**

- 15.00 - 15.30 Translations and HRQOL: What is the best approach? (M. Koller)
15.30 - 16.00 Minimum Clinically Important Change in QOL based on Clinical Anchors (J. Maringwa)
- 16.00 - 16.20 Coffee Break**
- 16.20 - 16.35 Quality of Life in elderly cancer patients (U. Wedding)
16.35 - 16.50 Quality of Life Tools for Elderly Patients (C. Johnson)
16.50 - 17.20 Looking back to go ahead (D. Osoba)
17.20 Goodbye address and symposium evaluation (A. Bottomley)

REGISTRATION FORM

Title	<input type="checkbox"/> Prof	<input type="checkbox"/> Dr	<input type="checkbox"/> Ms	<input type="checkbox"/> Mrs	<input type="checkbox"/> Mr
Last Name	_____				
Institution / Company	_____				
Department	_____				
Address	_____				
Town	_____	PostCode	_____	Country	_____
Phone	_____	Fax	_____		
E-mail	_____				
Gender	<input type="checkbox"/> Female	<input type="checkbox"/> Male	Age	_____	Nationality
Speciality	_____				
ESMO Member	<input type="checkbox"/> Yes	<input type="checkbox"/> No	ESMO Member ID Code	_____	
Signature	_____				Date
	_____				_____